03 November 2018 Written by CN1699 Services Article viewed 17 times (0 times in the last week)

A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness. This hyper-targeted approach offers hope to individuals living with spinocerebellar ataxia type 7 (SCA7) and validates a new form of therapy with the potential to treat neurogenetic diseases effectively and with far fewer side effects than other medications. Details of this therapy appear in the latest issue of Science Translational Medicine.


Written by: Duke University

Read full article: MedicalExpress

Photo Credit: The Scientist Magazine

Grace T

Marketing Manager - CN1699 Services